According to filings with the U.S. Securities and Exchange Commission, Cagent Vascular has raised $41 Million in new Series D funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the current round of funding include: U.S. Venture Partners (USVP) and Astoria Health Investors.

About Cagent Vascular
Cagent Vascular is a medical technology company that develops next-generation angioplasty balloons using proprietary Serration Technology for the treatment of cardiovascular disease. The companys core innovation, known as Serration Remodeling Therapy (SRT), is a novel approach to vessel preparation that gently remodels the artery to reduce recoil, optimize lumen gain, and support more durable clinical outcomes. Positioned as a technology leader in this space, Cagent Vasculars vision is to be the leader in angioplasty technology with the first and only serration balloon designed to restore blood flow. Its products and research focus on improving the treatment of cardiovascular disease, which the company highlights as a leading cause of mortality and poor quality of life worldwide. Through this focus on serration-based angioplasty solutions, Cagent Vascular aims to advance standard care in vascular interventions by offering more effective and predictable vessel remodeling.

To learn more, visit https://cagentvascular.com/
Linkedin: https://www.linkedin.com/company/cagent-vascular/

Contact:
Brian Walsh, Chief Executive Officer
https://www.linkedin.com/in/brianwalsh-medtech/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.